Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 in combination with Bevacizumab and/or Chemotherapy for Advanced HCC
NCT05976568Phase 3Not yet recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Sep 2023
- Primary completion
- Sep 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of QL1706 in hepatocellular carcinoma (HCC) (4 arms), sponsored by Qilu Pharmaceutical. Primary endpoints: Objective Response Rate, Incidence of Adverse Events and 1 more. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05976568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05976568.